z-logo
open-access-imgOpen Access
Curcumin Minimises Histopathological and Immunological Progression in the Ankle Joints of Collagen-Induced Arthritis Rats
Author(s) -
Taty Anna Kamarudin
Publication year - 2020
Publication title -
medicine and health
Language(s) - English
Resource type - Journals
eISSN - 2289-5728
pISSN - 1823-2140
DOI - 10.17576/mh.2020.1502.05
Subject(s) - curcumin , medicine , arthritis , rheumatoid arthritis , interleukin , pharmacology , cytokine
Curcumin is a traditionally used spice with a potential to treat various inflammatory diseases including arthritis. This study was aimed at observing curcumin’s effects on the histopathological progression and interleukin-1β (IL-1β) levels in collageninduced arthritis (CIA). Thirty male Sprague-Dawley rats (150+50 g) were divided into five random groups. A group was assigned as the normal control (CTRL), while the remaining were subcutaneously immunised with 150 μg of collagen emulsion on day 0. CTRL and CIA-Curcumin-d0 groups were supplemented daily with olive oil (1 ml/kg) and curcumin (110 mg/ml/kg) from day 0, respectively. The CIA-OV (negative control), CIA-Beta and CIA-Curcumin-d14 groups were given daily supplementation of olive oil (1 ml/kg), Betamethasone (0.5 mg/ml/kg), and curcumin (110 mg/ml/kg) from day 14, respectively. The daily oral supplementations continued until day 42. The study showed that CIA-Beta (**P<0.05) and CIACurcumin- d0 (**P=0.01) groups had significantly lower mean histological scores compared to CIA-OV, respectively. Serum IL-1β levels for CIA-Beta and CIACurcumin- d0 were not significantly raised on day 42 as to compared to day 0, and the mean increment of IL-1β levels from day 0 to day 42 were significantly lower (**P≤0.01) for all the CIA groups compared to CIA-OV. There was no significant difference in both mean histological scores and IL-1β levels of CIA-Curcumin-d0 compared to CIA-Beta. Early supplementation of curcumin could potentially minimise disease progression of CIA in rats.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here